| Beclomethasone Dipropionate | Norton Waterford | ||
| 40 mcg/actuation ; Inhalation Aerosol |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| None | None | ||
| None | |||
|
No
| |||
| Qvar Redihaler | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* (***** ****** ******) | ******* (***** ****** ******) |
| **** ******* *** ******* ****** * **** *** ***** *********** | **** ******** *** ********, ******** *** ******* ** ******** ******* | **** ******* *** ******* *** ****** *** ******** ***** | **** ******* *** ******* ****** ** ****-******* ******** ******** | **** ******* *** ******* ****** ** ****-******* ******** ******** | ****** ******** ******* | ******** *** ******* ******* | **** ******* *** ******* ****** ** ****-******* ******** ******** | ******** *** ******* ******* | ******** *** ******* ******* | ******** *** ******* ******* | ******** *** ******* ******* | ******** *** ******* ******* | ****** ******** ******* | *******-**** ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** \ ********* | *** **, **** | ******* | **** | *** ****** *** **** |
| Beclomethasone Dipropionate | Norton Waterford | ||
| 80 mcg/actuation ; Inhalation Aerosol |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| None | None | ||
| None | |||
|
No
| |||
| Qvar Redihaler | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* (***** ****** ******) | ******* (***** ****** ******) |
| **** ******* *** ******* ****** * **** *** ***** *********** | **** ******** *** ********, ******** *** ******* ** ******** ******* | **** ******* *** ******* *** ****** *** ******** ***** | **** ******* *** ******* ****** ** ****-******* ******** ******** | **** ******* *** ******* ****** ** ****-******* ******** ******** | ****** ******** ******* | ******** *** ******* ******* | **** ******* *** ******* ****** ** ****-******* ******** ******** | ******** *** ******* ******* | ******** *** ******* ******* | ******** *** ******* ******* | ******** *** ******* ******* | ******** *** ******* ******* | ****** ******** ******* | *******-**** ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** \ ********* | *** **, **** | ******* | **** | ******* *** **** *** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|